DGX

DGX

USD

Quest Diagnostics Incorporated Common Stock

$178.030-1.320 (-0.736%)

السعر في الوقت الحقيقي

Healthcare
Diagnostics & Research
الولايات المتحدة

مخطط الأسعار

Loading Chart...

المقاييس الرئيسية

مقاييس السوق
أساسيات الشركة
إحصاءات التداول

مقاييس السوق

الافتتاح

$179.350

الأعلى

$180.040

الأدنى

$176.310

الحجم

0.20M

أساسيات الشركة

القيمة السوقية

19.8B

الصناعة

Diagnostics & Research

البلد

United States

إحصاءات التداول

متوسط الحجم

0.90M

البورصة

NYQ

العملة

USD

نطاق 52 أسبوعاً

الأدنى $148.7الحالي $178.030الأعلى $197.55

أخبار ذات صلة

PR Newswire

New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis

Two blood tests, each involving multiple biomarkers, are highly accurate at identifying Alzheimer's disease pathology in symptomatic patients,...

عرض المزيد
New Study Demonstrates Accuracy of Two Quest AD-Detect® Tests for Alzheimer's Disease Diagnosis
Analyst Upgrades

Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $195

Barclays analyst Stephanie Davis maintains Quest Diagnostics with a Equal-Weight and raises the price target from $190 to $195.

عرض المزيد
Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $195
Analyst Upgrades

Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $205

Truist Securities analyst David Macdonald maintains Quest Diagnostics with a Hold and raises the price target from $195 to $205.

عرض المزيد
Truist Securities Maintains Hold on Quest Diagnostics, Raises Price Target to $205
Analyst Upgrades

Leerink Partners Maintains Outperform on Quest Diagnostics, Raises Price Target to $210

Leerink Partners analyst Michael Cherny maintains Quest Diagnostics with a Outperform and raises the price target from $203 to $210.

عرض المزيد
Leerink Partners Maintains Outperform on Quest Diagnostics, Raises Price Target to $210
PR Newswire

Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025

Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the third...

عرض المزيد
Quest Diagnostics Reports Third Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
Analyst Upgrades

Evercore ISI Group Maintains In-Line on Quest Diagnostics, Raises Price Target to $190

Evercore ISI Group analyst Elizabeth Anderson maintains Quest Diagnostics with a In-Line and raises the price target from $185 to $190.

ابق على اطلاع

تعيين تنبيهات الأسعار، الحصول على تحديثات تحليل الذكاء الاصطناعي وأخبار السوق في الوقت الحقيقي.